Brief: Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
05/12/2024 12:43
Dec 5 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PROVIDES CLINICAL UPDATE AND ANNOUNCES FIRST
COMPLETE
RESPONDER IN MDNA11 AND KEYTRUDA® (PEMBROLIZUMAB) COMBINATION
DOSE ESCALATION ARM OF THE ABILITY-1 STUDY
Source text: ID:nGNXb21FKm
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results